| Features: |
| Trastuzumab is a targeted therapy used in the treatment of certain types of cancer, most notably HER2-positive breast cancer. It specifically targets the human epidermal growth factor receptor 2 (HER2), a protein that is overexpressed in some types of breast cancer and other cancers. -Is a Her2 inhibitor used in breast cancer. Trastuzumab has revolutionized the treatment of HER2-positive breast cancer, significantly improving both response rates and overall survival. |
| Source: HalifaxProj(inhibit) |
| Type: |
| Akt1 is involved in cellular survival pathways, by inhibiting apoptotic processes; Akt2 is an important signaling molecule in the insulin signaling pathway. It is required to induce glucose transport. Inhibitors: -Curcumin: downregulate AKT phosphorylation and signaling. -Resveratrol -Quercetin: inhibit the PI3K/AKT pathway. -Epigallocatechin Gallate (EGCG) -Luteolin and Apigenin: inhibit AKT phosphorylation |
| 1101- | CA, | Tras, | Cooperative antitumor activities of carnosic acid and Trastuzumab in ERBB2+ breast cancer cells |
| - | in-vitro, | BC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:260 Target#:4 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid